RESEARCH PUBLICATIONS
2026
- Abeyakoon, C., et al. End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study. British Journal of Haematology, 2026;00:1–11. doi.org/10.1111/bjh.70689
- Alem, A., et al. Prognostic survival models for diffuse large B-cell lymphoma using statistical and machine learning approaches. npj Precision Oncology. 2026. https://doi.org/10.1038/s41698-026-01604-w
- Loh, Z., et al. Significant variations in first-line mantle cell lymphoma care—an Australasian Lymphoma and Related Diseases Registry study. Leukemia & Lymphoma, 1–9. doi.org/10.1080/10428194.2026.2673099
- Sungur S., et al. Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study. eJHaem. 2026: e70212. doi.org/10.1002/jha2.70212
- Yao Y., et al. Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study. European Journal of Haematology. 2026; 0:1–10. doi.org/10.1111/ejh.70295
2025
- Alem AZ, et al. Development and Validation of Prognostic Models for Treatment Response of Patients with B-Cell Lymphoma: Standard Statistical and Machine-Learning Approaches. J. Clin. Med. 2025. doi.org/10.3390/jcm14207445
- Chung E, et al. Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study. Haematologica. 2025. doi.org/10.3324/haematol.2025.287919
- Martynchyk A, et al. Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report. Intern Med J. 2025;55(6):937-943. doi.org/10.1111/imj.70037
- Wong EY, et al. Real-World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR). eJHaem. 2025;6:e1096. doi.org/10.1002/jha2.1096
- Wang L & Chung E, et al. Definitions and use of tumour bulk in phase 3 lymphoma trials: a comprehensive literature review. Blood Adv. 2025;9(9):2275-2284. doi.org/10.1182/bloodadvances.2024015072
2024
- Baggio D, et al. Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. Intern Med J. 2024;54(11):1223-1227. doi.org/10.1111/imj.16445
- Barraclough A, et al. Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica. 2024;109(10):3338-3345. doi.org/10.3324/haematol.2023.284538
- Shaw B & Chung E, et al. Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. eJHaem. 2024;1-8. doi.org/10.1002/jha2.870
2023
- Goh Z, et al. Characteristics and Outcomes of Older Patients with Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study. Clin Lymphoma Myeloma Leuk. 2023;23(5):370-378. doi.org/10.1016/j.clml.2023.01.014
2022
- Nguyen J, et al. Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. Eur J Haematol. 2022;110(4):386-395. doi.org/10.1111/ejh.13915
- Baggio D, et al. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leuk Lymphoma. 2022;64(3):621–627. doi.org/10.1080/10428194.2022.2157676
- Lymphoma and Related Diseases Registry Investigators. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Med Res Methodol. 2022;22:266. doi.org/10.1186/s12874-022-01728-0
RESEARCH PUBLICATIONS WITH CONSORTIA
2026
- Flerlage J, et al. Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses. Blood Adv. 2026 Apr 14:bloodadvances.2026020012. doi: 10.1182/bloodadvances.2026020012
2025
- Maurer M, et al. The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool. Blood Adv. 2025 Mar 25;9(6):1366-1369. doi: 10.1182/bloodadvances.2024014689
2024
- Binkley MS, et al. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. J Clin Oncol. 2024;42:2271-2280. doi.org/10.1200/JCO.23.01655
2023
- Hapgood G, et al. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood Adv. 2023;7(17):5047-5054. doi.org/10.1182/bloodadvances.2023010037
2022
- Rodday AM, et al. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Development and Validation of a Clinical Prediction Model from the HoLISTIC Consortium. J Clin Oncol. 2022;41:2076-2086. doi.org/10.1200/JCO.22.02473
OTHER PUBLICATIONS
2020
- Maqbool M, et al. A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 2020; 52, 167-178. https://doi.org/10.1016/j.pathol.2019.11.002